We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Lab-Based COVID-19 PCR Tests Fail to Distinguish New ‘Stealth’ Version of Omicron from Other Variants

By LabMedica International staff writers
Posted on 09 Dec 2021

Omicron, the new SARS-CoV-2 variant, lacks a specific feature that allows PCR tests to distinguish probable cases among COVID-19 positive individuals, according to a report by The Guardian.

Scientists claim to have identified a “stealth” version of Omicron that cannot be distinguished from other SARS-CoV-2 variants using PCR tests utilized by public health officials to gain an understanding of its spread globally. The first Omicron (B.1.1.529) case was reported to the World Health Organization (WHO) on November 24. Just two days later, the WHO designated the variant a Variant of Concern (VOC), based on its unusually large number of mutations and early evidence of its spread. Despite a series of rapidly implemented travel bans, it has now been reported in Africa, many European countries, and a few in Asian countries.

The newly-discovered variant of Omicron shares several mutations with the standard Omicron, but lacks a specific genetic change that allows probable cases to be flagged by lab-based PCR tests. Most PCR machines look for three genes in the virus, although Omicron (and the prior variant Alpha) test positive on only two of these machines due to a genetic change called a deletion in the “S” or spike gene in both Omicron and Alpha. As a result of this glitch, PCR tests that display the so-called “S gene target failure” are highly suggestive of Omicron infections. The commonly used tests can still detect the stealth variant of Omicron as coronavirus, and genomic testing can identify it as the Omicron variant, although routine PCR tests that deliver quicker results can fail to flag probable cases.

Following the discovery of the new form of the Omicron variant, researchers have now split the B.1.1.529 lineage into standard Omicron, known as BA.1, and the newer variant, known as BA.2. Some researchers have now termed the new variant as “stealth Omicron” due to its lack of deletion that allows it to be spotted by PCR tests. Despite falling under Omicron, the stealth variant is so genetically distinct that it could qualify as a new VOC if it spreads rapidly. Researchers are worried over the arrival of two variants, BA.1 and BA.2, in quick succession with shared mutations that could indicate public health surveillance “is missing a big piece of the puzzle”.

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.